Senores Pharmaceuticals Limited has announced that its officials will attend an investor conference scheduled for May 28, 2026. The meeting is being conducted pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting Details

The interaction is aimed at analysts and institutional investors. The company has specified that the discussions will be based solely on publicly available information. It explicitly stated that no unpublished price sensitive information (UPSI) is intended to be discussed during these interactions.

The schedule for the meeting is as follows:

Additional Information

The company noted that changes to the schedule may occur due to exigencies on the part of the host or the company. The disclosure was made by Vinay Kumar Mishra, Company Secretary and Compliance Officer.

Senores Pharmaceuticals reported a strong financial performance for the year ended March 31, 2026, with significant growth in revenue and profitability across all key segments. The Board of Directors approved the audited consolidated and standalone financial results for the quarter and financial year ended March 31, 2026, at its meeting held on May 14, 2026. Subsequently, the company issued a corrigendum correcting certain segmental revenue figures, year-on-year growth rates, and prior year comparatives that contained a typing error in the original media release. The statutory auditors, M/s. Pankaj R. Shah and Associates, issued an unmodified opinion on the financial statements. In compliance with Regulations 30 and 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company also held an Earnings Conference Call with analysts, institutional investors, funds, and other investors on May 14, 2026, with the audio recording now available on the company's website at senorespharma.com/investor-meet/ . The company confirmed that no Unpublished Price Sensitive Information was shared or discussed during the call.

FY27 Outlook

Senores Pharmaceuticals has guided for a revenue growth estimate of 30-40% for FY27, along with approximately 50-60% profit growth for the same period. This forward-looking guidance reflects the company's confidence in sustaining its growth trajectory, backed by an expanding ANDA pipeline, new acquisitions, and strengthened market access across regulated and emerging markets.

FY26 Financial Performance

For the full year FY26, the company reported total income of Rs. 664 crores, a 62% year-on-year increase. EBITDA for FY26 stood at Rs. 200 crores, surging 96% year-on-year. Net profit after tax (PAT) for the year stood at Rs. 122 crores, marking a 108% year-on-year growth. Earnings per share (EPS) for the year increased to ₹26.39 from ₹16.12 in the prior year. Cash Flow from Operations for FY26 stood at Rs. 75 crores, showing significant improvement over the previous year.

Q4FY26 Highlights

The fourth quarter of FY26 also demonstrated robust momentum. Total income for Q4FY26 reached Rs. 190 crores, up 58% year-on-year. EBITDA for the quarter surged 144% year-on-year to Rs. 62 crores. PAT for Q4FY26 rose to Rs. 37 crores, reflecting 105% year-on-year growth.

The following table presents the consolidated financial highlights for FY26 and Q4FY26:

Segmental Performance

The company's regulated markets segment was the standout performer, with revenue growing 74.6% for FY26 and 83.0% in Q4FY26. The branded generics business surged 385.3% year-on-year for FY26, with the portfolio receiving approvals from top multi-specialty and specialty hospitals. The emerging markets business maintained a steady trajectory, growing approximately 13% year-on-year for FY26, with EBITDA margin at approximately 12%.

The corrected segmental revenue figures, as per the corrigendum issued by the company, are presented below:

Strategic & Operational Highlights

Senores expanded its regulated markets pipeline significantly, with 51 approved ANDAs covering 151 strengths as of March 2026, up from 26 ANDAs as of March 2025. Over 30 of these approved ANDAs are yet to be commercialized, and 27 additional ANDAs covering 65+ strengths are under development. The company completed Phase 1 of the acquisition of a 75% equity stake in Apnar Pharmaceuticals, with Phase 2 (balance 25%) expected to be completed by Q2FY27. Initial revenues from the Apnar facility commenced in Q4FY26, with scale-up to peak revenue expected over the next 12–18 months.

In addition to the Apnar acquisition, the company entered into an agreement to acquire a 51% membership interest in Zoraya Pharmaceuticals, LLC, a USA-based entity, to strengthen vertical integration and direct commercialization of its ANDA portfolio. In April 2026, Senores entered into a 70% joint venture, Amerisyn, in the U.S., creating a direct pathway to supply pharmaceuticals to federal, veterans, and defense sectors.

Management Commentary

Commenting on the FY26 performance, Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited, said: "We have delivered a robust performance across segments in FY26, driven by operational discipline, consistent execution, and strong momentum in key growth areas despite an uncertain operating environment. Our approved ANDA portfolio has more than doubled during the year, increasing from 26 ANDAs as of March 2025 to 51 ANDAs as of March 2026, reflecting the scale and pace of our execution. We have expanded our manufacturing footprint and product portfolio through acquisition of Apnar Pharmaceuticals, which enhances scalability, deepens access to Regulated Markets, and expands CDMO-CMO opportunities. All in all, we continue to outperform on our stated commitments despite an uncertain environment, reflecting the strength of our long-term strategy, diversified business verticals and disciplined execution."

Corporate Governance Updates

During the board meeting, the company approved the resignation of Mr. Vinay Kumar Mishra as Company Secretary and Compliance Officer, effective from the close of business hours on June 10, 2026. Based on the Audit Committee's recommendation, the Board appointed Sharp & Tannan Associates, Chartered Accountants, as the Internal Auditor of the company for FY 2026-27.